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Soluble E-cadherin is a valid prognostic marker in
gastric carcinoma
A O O Chan, S K Lam, K M Chu, C M Lam, E Kwok, S Y Leung, S T Yuen, S Y K Law,
W M Hui, K C Lai, C Y Wong, H C Hu, C L Lai, J Wong
Abstract
Background—Gastric cancer remains a
major cause of cancer mortality globally
but no good prognostic tumour marker is
available. Soluble fragment of E-cadherin
protein has been reported to increase in
the sera of patients with cancer and
recently was found to be elevated in 67% of
patients with gastric cancer.
Aims—To investigate if serum soluble
E-cadherin is a valid prognostic marker in
gastric cancer.
Methods—Concentrations of soluble
E-cadherin from 116 patients with histo-
logically confirmed gastric adenocari-
noma and 40 healthy subjects were
measured using an immunoenzymomet-
ric method with a commercially available
sandwich ELISA kit based on monoclonal
antibodies.
Results—The logarithm of the means of
soluble E-cadherin concentration was sig-
nificantly higher in patients with gastric
cancers (mean 3.85 (SD 0.28)) than in
healthy subjects (3.71 (0.18)) (p=0.001),
and in palliative/conservatively treated
cancers (3.91 (0.35)) than in operable can-
cers (3.78 (0.19)) (p=0.015). The logarithm
of the concentrations correlated with
tumour size (p=0.032) and carcinoembry-
onic antigen concentrations (p=0.001).
The cut oV value calculated from discri-
minant analysis on operability and
inoperability/palliative treatment was
7025 ng/ml. Soluble E-cadherin concen-
trations higher than this cut oV value pre-
dicted tumour (T4) depth invasion
(p=0.020, confidence interval (CI) 1.008–
1.668) and palliative/conservative treat-
ment (p=0.023, CI 1.038–2.514). In
contrast, the relative risks for lymph node
(N2) metastasis, distant metastasis, and
stage III/IV disease were 1.41, 1.33, and
1.55 respectively, despite not reaching sta-
tistical significance.
Conclusion—Serum soluble E-cadherin is
a potential valid prognostic marker for
gastric cancer. A high concentration pre-
dicts palliative/conservative treatment
and T4 invasion.
(Gut 2001;48:808–811)
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Gastric cancer remains the second major cause
of cancer related deaths in the world.1 How-
ever, there is currently no satisfactory tumour
marker for diagnosis or monitoring disease
progress. The most frequently used tumour
markers in gastric cancer are carcinoembryonic
antigen (CEA) and CA19-9, but only a modest
proportion of patients have elevated levels of
these markers.
The cadherins are a major class of adhesion
molecules which play an important role in the
homotypic cell-cell adhesion and hence cancer
cell metastasis and invasion. E-cadherin is a
member of the cadherin family which is
expressed in all epithelial cells. The role of
E-cadherin in metastasis and invasion is
evidenced by the fact that the invasiveness of
epithelial tumour cell lines was inhibited in
vitro by transfection and expression of
E-cadherin cDNA, and induced again by
exposure to anti-E-cadherin monoclonal
antibodies.2–4 Under expression of E-cadherin
molecule has been found in various malig-
nancies and has potential value as a prognostic
marker.5
Serum soluble E-cadherin is the degradation
product of the cellular E-cadherin molecule. It
is found in the circulation of normal individu-
als but is particularly elevated in patients with
malignancies. Serum soluble E-cadherin has
been shown to be a potentially valuable
prognostic marker for carcinoma of the blad-
der.6 However, its prognostic value has not
been proved in colorectal cancer,7 and its value
in gastric cancer is controversial. Velikova and
colleagues8 were unable to show a significant
diVerence in serum soluble E-cadherin be-
tween patients with gastric cancer and normal
subjects, while Gofuku and colleagues9 showed
that concentrations were significantly elevated
in 67% of patients. The aim of the present
study was to investigate the value of serum
soluble E-cadherin as a prognostic marker in
patients with gastric cancer.
Methods
PATIENT SELECTION
All patients admitted from 1 January 1997 to
30 September 1998 to the Departments of
Medicine and Surgery, Queen Mary Hospital,
with histologically proved gastric carcinoma,
including both operable and inoperable tu-
mours, were recruited. The sera of 125 patients
were collected after gastric cancer was con-
firmed histologically and before operation or
initiation of chemotherapy. Nine patients were
excluded from the present analysis because two
were non-Chinese, one had serum collection
after tumour debulking, one had another
Abbreviations used in this paper: CEA,
carcinoembryonic antigen.
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synchronous tumour, and five had coincidental
liver cirrhosis. Therefore, the total number of
patients included in the analysis was 116. A
group of 40 healthy subjects was recruited as
controls.
PATIENT ASSESSMENT AND DEFINITIONS OF
TREATMENTS
After gastric cancer was confirmed histologi-
cally by endoscopic biopsy, the extent of
disease was assessed by chest x ray, endoscopic
ultrasound, and computer tomography or
ultrasound of the abdomen. Curative resection
was defined as UICC R0 resection. Palliative
treatment included UICC R1 or R2 resection,
gastrojejunostomy, or palliative chemotherapy.
Conservative treatment referred to those pa-
tients receiving symptomatic support only.
STAGING AND CLASSIFICATION OF GASTRIC
CANCER
Tumour was staged according to the criteria of
the Japanese Research Society for Gastric
Cancer10 and classified histologically according
to the WHO and Lauren’s classification.11
ASSAY OF SOLUBLE E-CADHERIN
Venous blood samples were collected into plain
tubes, allowed to clot, and within one hour of
collection were centrifuged at 800 g for 10
minutes at 4°C to obtain serum. Serum was
removed, aliquoted, and stored at −70°C until
assay. Concentrations of soluble E-cadherin
were measured with a commercially available
sandwich ELISA kit based on monoclonal
antibodies (Zymed Laboratories Inc., South
San Francisco, California, USA). All blood
samples were measured by an investigator who
was blinded to the clinical details and coded
data sheet. Each sample was measured twice.
The assay method has been described previ-
ously.12 In brief, the first monoclonal antibody,
HECD-1, was coated onto microtitre plate
wells to create the solid phase. Non-specific
binding was blocked by a blocking buVer.
Serum samples from patients and standard
solutions supplied were incubated in the
microtitre plate wells. The second monoclonal
antibody, SHE 13-1, labelled with peroxidase
was added. During incubation, human
E-cadherin molecule was trapped by the two
monoclonal antibodies as a sandwich. The
reaction between the peroxidase and substrate
solution (H2O2 and tetramethybenzidine) re-
sulted in colour development with intensities
proportional to the concentration of human
E-cadherin present in the samples and stand-
ards. The colour developed was measured with
the microtitre plate reader for measurement of
absorbance at 450 nm. Accurate sample
concentrations of human E-cadherin were
determined by comparing specific absorbances
with those obtained from the standards plotted
on a standard curve.
STATISTICAL METHODS
Data were collected and analysed using the
Statistical Package for the Social Sciences.
Logarithmic transformation was performed on
soluble E-cadherin data for conversion to a
normal distribution. Clinical and biochemical
parameters of patients are expressed as mean
(SD). Comparisons were performed using the
independent sample Student’s t test and the ÷2
test. DiVerences were considered significant
when p<0.05, and approaching statistical
significance when p<0.1 and >0.05. Cut oV
values of soluble E-cadherin concentration
were calculated by discriminant analysis.
Results
There were 75 men and 41 women in the
patient group with a mean age of 66 (14) years.
There were 19 men and 21 women in the con-
trol group with a mean age of 31 (10) years.
The sizes of the tumours measured from the
pathological specimens obtained after resec-
tion ranged from 0.5 cm to 18 cm (mean 4.8
(3.2) cm). Forty eight per cent of tumours were
located in the gastric antrum. Of those with
gastric resection specimen available for patho-
logical examination, 61% were of the
intestinal-type, 30% were the diVuse-type, and
9% were a mixed-type according to Lauren’s
classification. The percentage of patients with
stage I, II, III, and IV disease were 12.6%,
18.4%, 28.2%, and 40.8%, respectively. There-
fore, most patients presented at advanced
stages.
The means of the logarithm of soluble
E-cadherin concentration in patients with gas-
tric cancer were significantly higher than those
of normal healthy subjects (3.85 (0.28) v 3.71
(0.18); p=0.001). In contrast, the means of the
logarithm of soluble E-cadherin concentration
in patients with T4 invasion, liver metastasis,
distant metastasis, and stage III/IV disease
were higher than the means of other tumour
depth invasion, absence of liver metastasis,
absence of distant metastasis, and stage I/II
disease, respectively, with p values approaching
statistical significance (p=0.057, 0.067, 0.082,
0.086, respectively). The logarithm of soluble
E-cadherin concentration correlated with the
size of the tumour (p=0.032) and with the
logarithm of CEA concentration (p=0.001).
Fifty four patients underwent curative gastric
resection while 43 patients received palliative
treatment. Another 10 patients received con-
servative treatment only. Nine patients were
excluded from further analysis of their treat-
ment results because eight were operable but
medically unfit and one committed suicide
before receiving any treatment. The means of
the logarithm of soluble E-cadherin concentra-
tions in patients receiving palliative/
conservative treatment and those receiving
curative resection were 3.91 (0.35) and 3.78
(0.19), respectively (p=0.015).
The cut oV value for serum soluble
E-cadherin of normal subjects and patients
with gastric cancer was calculated as 5994
ng/ml; 27.5% of normal subjects and 51.7% of
patients were above this cut oV value. The cut
oV value for curative treatment and palliative/
conservative treatment was calculated as 7025
ng/ml. Concentrations higher than 7025 ng/ml
were used to predict the relative risks of various
poor prognostic factors (table 1). Patients with
soluble E-cadherin concentrations above the
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cut oV value were more likely to have T4 inva-
sion (p=0.020, confidence interval (CI) 1.008–
1.668) and palliative/conservative treatment
(p=0.023, CI 1.038–2.514). The relative risks
of N2 metastasis, distant metastasis, and stage
III/IV disease were 1.41, 1.33, and 1.55,
respectively (NS).
Discussion
During carcinogenesis, tumour cells have to
dissociate from one another before they can
invade or metastasise. Therefore, adhesion
molecules are expected to play an important
role in carcinogenesis and especially metasta-
sis. Decreased membranous expression of
E-cadherin molecules has been found in gastric
cancer13 14 and other malignancies such as
colon,15 16 pancreas,17 oesophagus,18 liver,19
prostate,20 bladder,21 22 breast,23 24 and head and
neck tumours.25 Disruption of membranous
expression of E-cadherin could be caused by
disturbed polarisation of the cell, or mutations
or partial deletions of the E-cadherin gene,26
resulting in a protein which is not transported
to the cell membrane. Direct correlation
between E-cadherin and grade of tumour
diVerentiation has been observed in some
tumours.20–22 In a multivariate retrospective
study of 413 patients with gastric cancer,
E-cadherin positive tumours had significantly
better three and five year survival rates than
E-cadherin negative tumours.27
Soluble E-cadherin, a 80 kDa peptide, is
considered to be the degradation product of
the 120 kDa intact E-cadherin generated by a
Ca2+ ion dependent proteolytic action.28 29 The
peptide was found in the circulation of healthy
subjects and was not dependent on age or sex.
It was elevated in patients with gastric
carcinoma and other malignancies.12 Increased
serum soluble E-cadherin concentrations have
also been found in pemphigoid or pemphigus
skin conditions,30–32 and in multiorgan failure.33
As E-cadherin is expressed in all epithelial
cells, any condition with rapid epithelial cell
turnover may lead to an increase in its concen-
tration. Therefore, patients with these condi-
tions and those with chronic inflammatory dis-
eases were excluded from our study. In
addition, patients with cirrhosis were also
excluded as we believe that in cirrhosis cell
turnover is rapid and may result in higher lev-
els of soluble E-cadherin. This has been
confirmed in our unpublished data. However,
it is also important to identify other conditions
that may significantly aVect soluble E-cadherin
concentrations.
The present study confirmed the observa-
tion that concentrations of soluble E-cadherin
in patients with gastric cancer were higher than
those in healthy subjects. However, higher
soluble E-cadherin concentrations were ob-
served both in our healthy subjects and patients
compared with those reported in the literature,
with a mean value of 5616 ng/ml versus 2515
ng/ml in healthy subjects, and 9344 ng/ml ver-
sus 4735 ng/ml in patients with gastric
carcinoma.9 Only Chinese subjects were re-
cruited to the study because we do not know if
racial diVerences have any eVect on soluble
E-cadherin concentrations. DiVerences in bio-
logical behaviour in gastric cancer between
Japan and the Western world have been
suggested and may account for the observed
diVerences in prognosis.34 Therefore, higher
E-cadherin concentrations in our patients and
normal controls could be due to racial
diVerences. In addition, the fact that most of
our patients had advanced disease may also
explain in part the high concentrations of solu-
ble E-cadherin. Consequently, each laboratory
should have its own reference range.
Our results showed that soluble E-cadherin
concentrations were elevated in patients receiv-
ing palliative/conservative treatment and were
correlated with the size of the gastric tumour.
Patients with soluble E-cadherin concentra-
tions higher than the 7025 ng/ml cut oV value
were more likely to have non-curative resec-
tion, possibly due to T4 invasion. In addition,
these patients were more likely to have stage III
or IV disease, although this was not statistically
significant. However, this observation was
biased by the fact that a large number of
patients with advanced disease were inoperable
and therefore their diseases could not be staged
thus rendering the results less significant.
Tumour size, depth of tumour invasion, and
operability are important prognostic factors in
patients with gastric carcinoma. Tumour size
has been reported as a simple prognostic indi-
cator for gastric carcinoma.35 Soluble
E-cadherin may originate from the rapid
turnover of tumour cells. Therefore, the bigger
the tumour size, the higher the soluble
E-cadherin concentration. The increase in
relative risk of metastases in patients with
higher soluble E-cadherin concentrations re-
flected the role of E-cadherin as an “invasion
suppressor molecule”.5 36
Our data showed that serum soluble
E-cadherin correlated with poor prognostic
markers. High serum soluble E-cadherin pre-
dicted T4 invasion and palliative/conservative
treatment. However, it was only elevated in a
subgroup of patients. Therefore, further stud-
ies should aim at identifying the subgroup of
gastric cancer patients who have elevated solu-
ble E-cadherin concentrations, thereby in-
creasing its sensitivity, comparing the prognos-
tic value of soluble E-cadherin and
conventional markers such as CEA in patients
with gastric cancer, and also identifying other
conditions that may aVect soluble E-cadherin
concentrations. In addition, prospective studies
should also be carried out to investigate
post-treatment soluble E-cadherin levels and
Table 1 Prediction of relative risks of various prognostic factors using concentrations of
soluble E-cadherin higher than the cut oV value (> 7025 ng/ml)
Factor Category
Relative
risk p Value
Confidence
interval
T T4 v T1 or T2 or T3 1.30 0.020 1.008–1.668
N N2 v N0 or N1 1.41 0.064* 0.944–2.118
M M1 v M0 1.33 0.073* 0.954–1.859
Staging Stage III or IV v stage I or II 1.55 0.164 0.82–2.913
Operability Palliative/conservative v operable 1.62 0.023 1.038–2.514
T, tumour; N, lymph node; M, metastasis.
p<0.05 is considered statistically significant and is indicated by bold type; p<0.1 but >0.05 is con-
sidered approaching statistical significance and is indicated by an asterisk.
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their role in therapeutic monitoring in patients
with gastric cancer.
Presented in part at the Digestive Disease Week, Orlando, USA,
May 1999, and published in abstract form in Gastroenterology
1999;116:A388. The authors are indebted to Professor Bart
Hsi, Professor of Biometry, University of Texas, School of Pub-
lic Health, Houston, for expert advice on statistical analysis.
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